Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
euglena Co., Ltd. ( (JP:2931) ) just unveiled an announcement.
Euglena Co., Ltd., a Prime Market-listed healthcare player, has been reshaping its profit structure while deepening its focus on direct-to-consumer offerings and M&A-driven expansion. The group continues to position its healthcare operations as a primary growth engine within its broader portfolio.
For fiscal 2025, the company reported record net sales and sharply improved profitability, with operating profit rising more than tenfold year on year alongside strong gains in adjusted EBITDA and ordinary profit. Reflecting this performance and a stronger financial base, Euglena will pay its first-ever 20th anniversary special dividend of JPY 2 per share, underscoring management’s confidence in the success of its two-year profit reform program and the momentum in its healthcare business.
The most recent analyst rating on (JP:2931) stock is a Hold with a Yen389.00 price target. To see the full list of analyst forecasts on euglena Co., Ltd. stock, see the JP:2931 Stock Forecast page.
More about euglena Co., Ltd.
Euglena Co., Ltd., listed on the Prime Market of the Tokyo Stock Exchange under securities code 2931, operates in the healthcare sector with a focus on direct-to-consumer and other health-related businesses. The company has been pursuing profit structure reforms and expanding its healthcare operations, including through mergers and acquisitions, to drive organic and inorganic growth.
Average Trading Volume: 973,347
Technical Sentiment Signal: Sell
Current Market Cap: Yen57.09B
Learn more about 2931 stock on TipRanks’ Stock Analysis page.